# Scilex Holding Co > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Scilex Holding Co). ## Overview Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products. Its commercial portfolio includes ZTlido, ELYXYB, and GLOPERBA, and it also develops product candidates such as SP-103, SP-104, and SEMDEXA through its operating subsidiaries and related collaborations. ## Products & services • ZTlido lidocaine topical patch • ELYXYB oral solution for migraine • GLOPERBA colchicine oral solution • SP-103 and SP-104 product candidates • SEMDEXA development program • Product commercialization and distribution - **Commercial products** (100%) — Approved pharmaceutical products sold in the U.S., including ZTlido, ELYXYB and GLOPERBA. - **Product candidates** (0%) — Development-stage programs for pain and related therapeutic areas, including SP-103, SP-104 and SEMDEXA. - **Licensing and royalty arrangements** (0%) — Rights, royalties and supply arrangements tied to product commercialization and manufacturing partners. - ZTlido lidocaine topical patch - ELYXYB oral solution for migraine - GLOPERBA colchicine oral solution - SP-103 and SP-104 product candidates - SEMDEXA development program - Product commercialization and distribution ## Customers Scilex sells primarily into the U.S. pharmaceutical channel, where prescription products are purchased through wholesalers, pharmacies, and other distribution intermediaries before reaching patients. Demand is driven by physicians, payors, and patients in pain management and migraine care, while GLOPERBA serves a specialty colchicine market. The company also relies on manufacturing and development partners for supply and commercialization support. - **U.S. prescription drug distribution channel** (primary) — Wholesalers, regional distributors and pharmacies that buy and distribute ZTlido, ELYXYB and GLOPERBA. - **Physicians and prescribers** (primary) — Clinicians who prescribe the company's branded therapies for pain, migraine and related indications. - **Payors and formulary managers** (primary) — Commercial and government reimbursement decision-makers that affect access, rebates and net sales. - **Patients** (secondary) — End users of the company's prescription products, especially in non-opioid pain and migraine care. - **Development partners** (secondary) — Counterparties in licensing, supply and joint venture arrangements that support pipeline development. - Wholesalers and pharmacies that distribute prescription products - Physicians treating pain, migraine, and gout-related conditions - Payors and formulary decision-makers influencing access and rebates - Patients using branded non-opioid therapies through prescriptions - Development and manufacturing partners supporting product supply ## Geography Scilex is primarily a United States business, with net revenue from product sales of ZTlido, ELYXYB and GLOPERBA generated in the U.S. The company also has product and royalty arrangements tied to Canada and foreign suppliers, which create some cross-border operating exposure even though commercialization is centered in the U.S. Its development and supply chain depends on third-party manufacturers and partners outside the U.S., including Japanese suppliers for lidocaine tape products. - United States is the core commercial market for all current products - Canada is relevant for ELYXYB territorial rights and royalties - Foreign manufacturing and supply partners support ZTlido and other products - Cross-border payments create foreign exchange exposure - Commercialization is concentrated in U.S. prescription drug channels ## Strategy Scilex is focused on expanding commercial awareness and utilization of its marketed products while advancing its pain and neurology pipeline. The company also uses partnerships, licensing and financing transactions to support development programs and maintain flexibility across commercialization and R&D. Its strategy depends on building prescription demand for current products while progressing product candidates toward regulatory milestones. - **Grow branded product adoption** (short-term) — Current revenue depends on prescription uptake and channel access for ZTlido, ELYXYB and GLOPERBA. - **Advance pipeline programs** (medium-term) — Future value depends on clinical and regulatory progress for product candidates in pain and related indications. - **Use partnerships and financing to fund development** (short-term) — The business model requires external capital and collaboration to support commercialization and R&D. - Expand sales and digital marketing for ZTlido, GLOPERBA and ELYXYB - Advance SP-103, SP-104 and SEMDEXA through clinical and regulatory work - Use partnerships and joint ventures to broaden pipeline optionality - Support commercialization with external manufacturing and distribution - Access capital through equity, debt and strategic transactions ## Risks Scilex faces the typical risks of a specialty biopharmaceutical company: dependence on a small number of products, uncertain prescription demand, reimbursement pressure and clinical development risk. It also has meaningful financing, supply chain and foreign exchange exposure because it relies on third-party manufacturers, royalty arrangements and external capital to support operations and pipeline development. - **Dependence on a small commercial portfolio** [high] — Revenue is concentrated in a few branded products, so any slowdown in prescription demand or access can materially affect results. - **Financing and going-concern risk** [high] — The company expects to need additional capital to fund operations and development, which can dilute shareholders or constrain execution. - **Supply chain and single-source dependency** [medium] — Commercial supply and clinical materials are obtained from third-party and sometimes sole-source manufacturers, creating disruption risk. - **Reimbursement and gross-to-net pressure** [medium] — Rebates, chargebacks, returns and discounts reduce realized revenue and can vary with payer mix and channel dynamics. - **Clinical and regulatory development risk** [high] — Pipeline assets may not demonstrate efficacy, safety or approvability, which would limit future growth options. - Limited operating history and continuing losses increase financing risk - Commercial demand for ZTlido, ELYXYB and GLOPERBA can fluctuate - Dependence on third-party manufacturers and single-source suppliers - Reimbursement, rebates and formulary access affect net sales - Pipeline programs may fail in clinical or regulatory development - Foreign supplier payments create currency and cross-border execution risk ## Accounting Scilex's reported revenue is affected by gross-to-net adjustments, including rebates, chargebacks, returns and prompt-payment discounts, which can materially change net sales versus gross billings. Investors should also watch royalty accounting, fair value measurements for financing instruments and deferred consideration, and impairment or write-down risk on inventory and acquired intangible assets. Because the company relies on external financing and development assets, valuation judgments can have a meaningful effect on reported results. - **Gross-to-net revenue adjustments** — Affects reported revenue and receivables - **Royalty liabilities** — Affects cost of revenue and current liabilities - **Inventory valuation** — Affects gross margin and operating results - **Fair value measurements** — Affects non-cash gains/losses and balance sheet values - **Intangible assets and in-process R&D** — Affects asset values and future expense recognition - Gross-to-net deductions reduce reported net revenue - Royalty obligations affect cost of revenue and accrued liabilities - Inventory write-downs can occur for expiring product stock - Fair value estimates matter for notes, warrants and JV-related instruments - Acquired intangible assets and in-process R&D may require impairment testing --- *Last updated: 2026-04-29T04:57:45.623724+00:00*